$HSTM

HealthStream (NASDAQ:HSTM) Declares Stock Buyback Program

HealthStream (NASDAQ:HSTM) announced that its Board of Directors has approved a stock buyback program of $10.0 million, allowing the repurchase of up to 1.7% of its shares. This decision often signals the board's belief that the company's shares are undervalued. The company also reported strong quarterly earnings, beating analyst expectations, and increased its quarterly dividend.

Original reporting
MarketBeat · MarketBeat
Published Mar 14, 2026, 2:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 14, 2026, 3:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HealthStream (NASDAQ:HSTM) Declares Stock Buyback Program — source image
Decision brief

The 30-second read

$HSTMBullishMed
01

Why it matters

The buyback and earnings beat likely reflect strong operational performance, which could lead to increased investor confidence.

02

Market read

The news is highly relevant for investors holding or considering HSTM, with potential short-term price appreciation.

03

What to watch

Potential macroeconomic headwinds or sector-specific challenges could offset the positive effects of the buyback and earnings beat.

Timing: Immediate, as the buyback program is announced now and may influence trading today and in the near future.

Background

HealthStream is a provider of workforce solutions for the healthcare industry, with recent positive earnings and strategic initiatives.

Company-level read

Ticker impact

$HSTMBullishHigh confidence
Context

The news directly pertains to HealthStream (NASDAQ:HSTM), indicating a positive corporate action and strong earnings report.

Expected impact

Moderate upward pressure on HSTM stock in the short to medium term.

Evidence & confidence

The buyback reduces share count, potentially increasing earnings per share, while earnings beat expectations reinforce positive sentiment. The combined effect is likely to support a price increase.

Market effects

The health technology and life sciences sectors may see positive sentiment, especially if other companies announce buybacks or earnings beats.

Limited regional impact; primarily affects US-based healthcare and tech sectors.

Minimal; the news is company-specific with limited global market implications.

Counterpoint

Some investors may view the buyback as a sign that the company lacks better growth opportunities, potentially limiting future upside.

Key entities

  • HealthStream, Inc.

    A provider of workforce solutions for the healthcare industry.

Related articles

$NVSLowAI 8/10

Back to Back Heart Drug Failures at Novartis and Novo Nordisk Undercut Two Leading Theories of Cardiovascular Risk

Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed in Phase 3 trials, testing different cardiovascular risk theories. Both drugs did not reduce cardiovascular events despite lowering targets. Novartis reported pelacarsen's Lp(a)HORIZON trial results, while Novo Nordisk halted ziltivekimab's HERMES and ATHENA trials. Analysts estimated pelacarsen's peak sales at $4B-$6B. Both companies have other trials ongoing.

$BAHighAI 9/10

US Navy awards Boeing first MQ-25A Stingray production contract

The US Navy awarded Boeing a $562M contract for the first three MQ-25A Stingray unmanned aerial refueling aircraft, with deliveries expected in 2029. The contract also funds components for three more aircraft. The MQ-25 program aims to produce 67 operational aircraft and nine test vehicles, with the Stingray designed to extend the service life of F/A-18 Super Hornet fighters by handling refueling missions.